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cTAGE-1 is a cutaneous-T-cell-lymphoma-speci¢c tu-
mor antigen recently identi¢ed by serologic identi¢ca-
tion of antigens by recombinant expression cloning.
This study was aimed at identifying and characterizing
related genes. Rapid ampli¢cation of cDNA ends and
DNA screening led to ¢ve new members of the cTAGE
gene family belonging to four di¡erent genes, two
of which were di¡erentially spliced (cTAGE-1/2 and
cTAGE-5). Expression analysis using reverse transcrip-
tion polymerase chain reaction revealed that cTAGE-1,
cTAGE-1B, and cTAGE-5A expression was restricted to
testis and tumor tissues, whereas the other cTAGE
members were found in two to eight other normal tis-
sues (of 27 tissues tested).Tumor-speci¢c protein expres-
sion of cTAGE-5 was con¢rmed by Western blotting.
Sero-reactivity against cTAGE-1, cTAGE-4, cTAGE-
5A, and cTAGE-5B was found only in tumor patients
(cutaneous T cell lymphoma and melanoma). The im-
munogenic epitope of cTAGE-1 was determined by
using epitope mapping and sera of two cutaneous T cell
lymphoma patients. Moreover, cTAGE-1, cTAGE-4,
cTAGE-5A, and cTAGE-5B could be detected in most
types of tumor tissues and cell lines at variable frequen-
cies, including those of cutaneous T cell lymphoma,
melanoma, head and neck squamous cell carcinoma,
breast carcinoma, and colon carcinoma. We conclude
that cTAGE-1 and cTAGE-5 are new cancer germline
antigens and that tumor-speci¢c splicing of cTAGE
genes may lead to further candidate proteins for speci¢c
immunotherapy of cutaneous T cell lymphoma and
other malignancies. Key words: cancer-testis antigens/
CTCL/melanoma/sero-reactivity/tumor immunology. J Invest
Dermatol 121:198 ^206, 2003
C
utaneous T cell lymphoma (CTCL) summarizes a
heterogeneous group of T cell malignancies charac-
terized by primary manifestation in the skin, which
originate in most cases from CD4-T lymphocytes
(Burg et al, 1997;Willemze et al, 1997). The most fre-
quent forms of CTCL are Mycosis fungoides and the leukemic
varient seŁ zary syndrome (Burg et al, 1997; Weinstock and Horn,
1988). Therapeutic approaches vary between the di¡erent types
of CTCL, but are generally successful in early stages but often
not in the aggressive, later stages of the disease. Immunologic
therapies such as vaccination with peptides or peptide-loaded
dendritic cells (Nestle et al, 1998; Nestle, 2000; Rosenberg, 2001)
could be a promising alternative, but validated tumor-speci¢c
antigens are still lacking for the treatment of CTCL, whereas for
melanoma a variety of tumor antigens and immune responses are
known (Renkvist et al, 2001).
The T cell receptor (TCR) has been proposed as a tumor-spe-
ci¢c target (Berger et al, 1998) and recently an adenovirus-
mediated vaccination with TCR-a and TCR-b chains fused to
an immunogenic protein has been demonstrated to protect
against tumor challenge in a mouse model (Wong and Levy,
2000). The disadvantage of this kind of treatment is the high
grade of individualization needed, and the fact that the proof of
principle is still lacking in humans. Two interesting cell surface
proteins have recently been discovered for CTCL (Bagot et al,
2001a; Nikolova et al, 2001), although their immunotherapeutic
usage has still to be proven.
CD8þ reactive in¢ltrates have been shown to be CTCL speci-
¢c and lytic (Berger et al, 1996; Bagot et al, 1998). In a recent study,
Vermeer et al (2001) could demonstrate that the percentage of in-
¢ltrating CD8þ T cells within biopsy samples of mycosis fun-
goides correlated signi¢cantly with prognosis. This suggests an
important role for the CD8þ cytotoxicT lymphocytes in antitu-
mor response in CTCL and further supports the idea of an im-
munologic therapy for this disease (Bagot et al, 2001b; Edelson,
2001). Yet, a set of speci¢c targets is still needed in order to com-
pose such a strategy without the drawback of immune escape
from a singular antigen.
By a SEREX (serologic identi¢cation of antigens by recombi-
nant expression cloning) approach using a testis phage library and
sera of patients su¡ering from CTCL, we have recently identi¢ed
a new potential target named cTAGE-1 (CTCL associated antigen
1, AF177229), which is expressed in around 35% of the tested
CTCL tumor specimens (Eichmˇller et al, 2001). The expression
of cTAGE-1 within normal tissues is restricted to testis, which
makes it very attractive for immune therapy as the testis is im-
mune privileged with low or even absent expression of human
leukocyte antigens (Chen and Old, 1999) and adds it to the still
increasing family of so-called cancer-testis antigens (Old, 2001).
Sequence analysis, database searches, and Northern blot analy-
sis suggested that cTAGE-1 is an alternative splicing product of a
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larger gene and may belong to a gene family (Eichmˇller et al,
2001). Thus this study aimed at the identi¢cation of the cTAGE
family and the evaluation of its members as putative tumor-spe-
ci¢c targets. We have used rapid ampli¢cation of cDNA ends
(RACE) elongation, library screening by DNA probes, and data-
base analyses for unraveling homologous genes, as well as reverse
transcription polymerase chain reaction (RT-PCR), Northern,
Southern, andWestern blotting, and SEREX for further charac-
terization of the new genes.
MATERIALS AND METHODS
Tissues and cell lines Tissue specimens were obtained from tumor
tissues during routine surgical treatment with the permission of the local
ethical board. Specimens were obtained from 19 CTCL including 14
mycosis fungoides (up to four cases stage I, ¢ve cases stage II, and ¢ve
cases stage IV), three SeŁ zary syndromes, one T-zone lymphoma, and one
CD30þ lymphoma, as well as 31 colon tumors, 28 head and neck
squamous cell carcinomas, and 23 breast carcinomas. Additionally, four
CTCL cell lines were used for RNA isolation including the mycosis
fungoides derived MyLa (Kaltoft et al, 1992), the SeŁ zary syndrome cell
line SeAx (Kaltoft et al, 1988), HH (lymphomatoide papulosis, ATCC
number CRL-2105), and HuT-78 (SeŁ zary syndrome, ATCC number TIB-
161). As non-CTCL cell lines we used 28 melanoma cell lines, six head and
neck squamous cell carcinoma cell lines, and eight colon carcinoma cell
lines.
A large number of control cDNAs each derived from several donor
samples were used to analyze expression speci¢city of the new genes:
human multiple fetal tissue cDNA panel (Becton Dickinson Clontech,
Palo Alto, CA; content: fetal brain, heart, kidney, liver, lung, skeletal
muscle, spleen, thymus) and cDNA made from RNA panels or
individual RNAs (Becton Dickinson Clontech; content: bone marrow,
brain, colon, heart, kidney, liver, lung, breast, ovary, placenta, peripheral
blood lymphocytes, prostate, skeletal muscle, skin, small intestine, spleen,
stomach, testis, thymus, trachea). All experiments handling human tissue
were carried out in accordance to Helsinki principles.
RNA extraction and RT-PCR Total RNAwas isolated using a variant
of the guanidinium thiocyanate/phenol method (peqGold TriFast, Peqlab,
Erlangen, Germany) and treated with DNase. cDNA was obtained using
a ¢rst strand cDNA synthesis kit (Roche Diagnostics, Mannheim,
Germany).
RT-PCRwas done as described previously (Eichmˇller et al, 2002). The
quality of the cDNA was tested by RT-PCR using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) primer (forward, gtttacatgt tccaatatga
ttccac; reverse, tcatatttgg caggtttttc tagac; 571C annealing temperature;
product size 638 bp; all primers are given in 5030 notation). The following
primer pairs were used to distinguish all di¡erent cTAGE members,
whereby primer setsIII were used for the analysis of cTAGE-1/2 splicing
variants (cf. Fig 1): primer set I (forward, ctcctgactt ctttcccaac ctttacc;
reverse, tgcaattccc acctaacttc cattctg; 601C, 714 bp), primer set II (forward,
ctctccccgc tgaaaatgaa gcaac; reverse, gcttagggaa gacgaaggga aggaa; 631C,
1002 bp), primer sets I-III (forward, tagggctaac cctcagccat ac; reverse,
ctccttctca aagctggcat tc; 631C, 364 bp), cTAGE-3 (forward, aacagaaagt
taatgactga gttatatc; reverse, cactctatct tcagaatgtg ggggtggg; 601C, 1195 bp),
cTAGE-4 (forward, gccataaaca gctttttcag caag; reverse, ttttaaactt ctggttctgc
tggtc; 601C, 1270 bp), cTAGE-5A (forward, ccagcacttg gcactttatt cg;
reverse, tatttcatcc tcaagttcag aatt; 551C, 578 bp), cTAGE-5B (forward,
ctctccctgc tgaaaatgaa gccac; reverse, tcgttagtct catccgccaa tgcttc; 601C, 308
bp), cTAGE-5C/MGEA-6 (forward, gtgtcatcat tttgagcttt gg; reverse,
tgcttcactg cctttccttc; 501C, 107 bp, published by Heckel et al (1997)), and
cTAGE-5D/MGEA-11 (forward, agcatttggc agaggctcac; reverse, tggaatcaaa
cctgagggga ac; 601C, 706 bp). The primers had to be designed in
consideration of sequence homologies between cTAGE members
negotiating primer sensitivity.
In order to control speci¢city of the RT-PCR detection, all PCR
products were separated, blotted onto nitrocellulose membranes, and
hybridized using digoxigenin-labeled plasmid-PCR products as probes
according to the manufacturer’s protocol (Roche Diagnostics).
RACE-PCR (rapid ampli¢cation of cDNA ends) was done using
primers located within cTAGE-1 both in 50 and 30 directions to get the
full-length gene (50 primer, tccttcccct tgccacagca agagaaaagc agaac; 30
primer, tgcaagctgg gccaccaagc cattgcttc), and starting within cTAGE-2 in
the 30 direction (primer, tttcccccca cctcctccag gaaccgtg). As target, RNA
from testis and CTCL cell lines was ampli¢ed using a RACE kit (SmartTM
cDNA ampli¢cation kit; Becton Dickinson Clontech).
Library screening by a DNA probe Similar to the SEREX approach,
a testis cDNA library was screened using cTAGE-1- and cTAGE-2-speci¢c
probes to identify homologous genes (Usener et al, 2003). Brie£y, speci¢c
DNA probes were obtained by PCR using cTAGE-1- and cTAGE-2-
speci¢c primers and the appropriate plasmids as targets. Twenty-¢ve
micrograms DNA of each PCR was digoxigenin labeled (Roche
Diagnostics), pooled, and diluted in 50 ml Dig Easy Hyb solution. The
testis phage library that was used for the SEREX screening and cTAGE-1
isolation (Eichmˇller et al, 2001) was recombinantly expressed and RNA
was blotted to nitrocellulose membranes. Membranes were prehybridized
(Dig Easy Hyb; 2 h; 451C), and hybridized with the probes (overnight,
451C). Positive clones were identi¢ed with a digoxigenin-speci¢c
antibody coupled to an alkaline phosphatase, which catalyzed BCIP and
NBT to a violet color. Clones were isolated to monoclonality, plasmid
was excised (in vivo excision according to the manufacturer’s protocol;
Stratagene), and the insert was sequenced. Moreover, serum reactivity to
the newly identi¢ed phagemid clones was analyzed by a secondary
SEREX screen as described previously (Eichmˇller et al, 2001; Usener
et al, 2003). Sera from up to 30 CTCL patients, 15 melanoma patients, and
17 healthy donors were used to screen each of the phage clones in at least
two independent experiments.
Epitope mapping Using epitope mapping as previously described
(Kneissel et al, 1999) we determined the immunogenic epitope of cTAGE-
1 as recognized by patients’antibodies. Brie£y, 15mer peptides with an o¡set
Figure1. Graphical alignment of cTAGE-1, cTAGE-1B, cTAGE-1C,
cTAGE-2, cTAGE-2s, and chromosome 18p11.2. Additionally, the pre-
dictions by the computer programs Genscan and HMMGene are indicated.
In the lower part the localization of all identi¢ed mRNA sequences in-
cluding two expressed sequence tag clones (cTAGE-1B and cTAGE-1C),
which were re-sequenced by us, are indicated. Note that the open reading
frames of cTAGE-1 and cTAGE-2 are located at di¡erent chromosomal
sites. cTAGE-2s is a postulated splicing variant (see text). The expression
of the di¡erent splicing variants is indicated in the right table. Note that
coexpression of cTAGE-1 and cTAGE-1C instead of or parallel to cTAGE-
1B expression is possible, as well as simultaneous expression of cTAGE-1C
in cTAGE-2s-positive specimens.
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by one amino acid covering all possible open reading frames on cTAGE-1
were synthesized on polyethylene-glycol-activated cellulose membrane.
The membranes were blocked with 10% milk, 5% sucrose, and 1casein
block (Sigma-Genosys, Cambridge, U.K.) in TBS-T (Tris-bu¡ered saline
containing 0.05% Tween-20). Membranes were incubated with CTCL
patients’ or normal sera diluted 1:500 in incubation bu¡er (TBS-T
containing 0.05% milk, 5% sucrose, 1casein block) for 2 h followed by
incubation with a peroxidase-coupled goat antihuman IgG (Hþ L)
(Dianova) diluted 1:10,000 for 1 h at room temperature. Antibody binding
was visualized by enhanced chemiluminescence staining (Amersham
Bioscience).
Northern and Southern blotting RNA from normal tissues (Becton
Dickinson Clontech) as well as RNA from cell lines from di¡erent
tumor entities (CTCL, melanoma, and colon carcinoma) was used for
Northern blotting. RNAwas blotted onto nylon membranes (Hybond N,
Amersham Bioscience) and ¢xed by ultraviolet crosslinking. The probes
were obtained by gene-speci¢c PCR using a cTAGE-2 plasmid and were
labeled by means of a Redi Prime II kit and 32P-dCTP (Amersham
Bioscience). Membranes were prehybridized (2 h at 551C), incubated with
the probe overnight at 551C, and subsequently washed in progressively
higher stringency (2 sodium citrate/chloride bu¡er (SSC)/0.1 sodium
dodecyl sulfate (SDS) at 551C for 15 min and 0.2 SSC/0.1 SDS at 651C
for 5 min). Autoradiography was conducted at ^801C for up to 5 d.
Filters were rehybridized with GAPDH probe to prove RNA integrity
and to compare RNA amount.
For Southern blotting, genomic DNAwas isolated from the CTCL cell
lines HH, HuT-78, MyLa, and SeAx (blood and cell culture DNAmini kit;
Qiagen, Hilden, Germany), cut by HindIII, separated, and blotted onto
positively charged nylon membranes. PCR products of cTAGE-1 and
cTAGE-2 plasmids were used as probes for labeling. After prehybri-
dization (6 SSC and 2Denhardt; 2 h at 631C) membranes were incu-
bated with the speci¢c probe (3 SSC, 1Denhardt, overnight at 601C)
and washed (2 SSC at 551C and 0.2 SSC at 601C, 2 30 min each). As
negative control we used a radioactive-labeled empty plasmid (pUC18).
Western blot analysis Two polyclonal rabbit antibodies (K64 and K65)
were raised against synthetic peptides derived from the open reading frame
of cTAGE-5A (amino acids 756^770: GLIPPSNEPATEHPE). This epitope
can be found in cTAGE-5A, cTAGE-5C, and cTAGE-5D, but not in
cTAGE-5B. The synthetic peptide was coupled to KLH and two rabbits
were immunized and boosted for two times each. A part of each serum
was puri¢ed by an a⁄nity puri¢cation carried out on a CnBr-Sepharose
column loaded with synthetic peptide (custom antibodies; synthesis of the
peptides, immunization, and puri¢cation by Biogenes, Berlin,
Germany).
Proteins for Western blotting were isolated with the peqGold TriFast
System (Peqlab) or obtained commercially (normal tissues: bone marrow,
brain, colon, placenta, prostate, spleen, skeletal muscle, small intestine,
trachea, stomach, testis; BioChain Institute, Hayward, CA, and Becton
Dickinson Clontech). Equal amounts of protein were separated by 12%
SDS polyacrylamide gel electrophoresis and blotted to a Hybond
nitrocellulose membrane (Amersham Bioscience). Membranes were
blocked with 5% dry milk in phosphate-bu¡ered saline/0.1% Tween
(PBS-T) for at least 1 h and washed three times in PBS-T. Membranes
were incubated with the cTAGE-5A antibody (1:10,000 in PBS-T
containing 0.5% milk and 0.5% bovine serum albumin BSA) overnight
at 41C and subsequently washed three times in PBS-T. A horseradish-
peroxidase-conjugated antirabbit antibody was used as secondary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA; 1:10,000 in PBS-T
containing 0.5% milk and 0.5% BSA; 1 h at room temperature). After
another wash in PBS-T (three times), antibody binding was visualized by
enhanced chemoluminescence (Western blot analysis system; Amersham
Bioscience). After stripping (2% SDS, 62.5 mM Tris at pH 6.7, and
100 mM b-mercaptoethanol; 561C for 30 min) equivalent loading was
con¢rmed by an additional hybridization using a monoclonal mouse anti-
b-actin antibody (1:5000; Santa Cruz).
RESULTS
cTAGE-1 and cTAGE-2 Analysis of cTAGE-1 indicated that
this mRNA might be an alternative splicing variant at the 30
end of a longer gene (Eichmˇller et al, 2001). This could be
con¢rmed by a 50 RACE using a testis RACE-cDNA
unraveling a 4.4 kb sequence in agreement with the size
depicted by Northern blot analysis (Eichmˇller et al, 2001). This
gene shows a clear open reading frame from bp 113 to bp 2377
representing an 86 kDa protein and was named cTAGE-2
(Accession number AF273058).
We had already identi¢ed chromosome 18p11.2 as the genomic
localization of cTAGE-1 (Eichmˇller et al, 2001) and cTAGE-2 ¢ts
to the same chromosomal region as an unspliced sequence with
99.6% similarity (Fig 1). Two homologous expressed sequence
tags derived from a testis library (Soares testis NHT), which
were named IMAGp998F133560 (Accession number AA868597)
and IMAGp998P031789 (Accession number AA399523), were
obtained from the Resource Center of the German Human
Genome Project (Berlin and Heidelberg) and sequenced. They
¢tted also to chromosome 18p11.2, but spanned over di¡erent
parts of cTAGE-1 and partly cTAGE-2, with an additional gap
within IMAGp998F133560, and were renamed cTAGE-1B and
cTAGE-1C (Fig 1).
We used gene-¢nding programs (GCG: Genscan, HMMGene)
to search for possible promoter sequences and exons on
chromosome 18p11.2. In fact, Genscan could identify a promoter
2.5 kb upstream of cTAGE-2, an initializing exon, and one
terminating exon (Fig 1). As Genscan does not predict
untranslated regions, the di¡erences in the 30 end are not
relevant. The coding regions predicted by HMMGene were
shorter, but spanned a larger part of chromosome 18p11.2
especially in the 30 direction. The open reading frame of cTAGE-
2 and the predicted terminal exon largely overlap, but the
predicted structure at the 50 end di¡ered from all experimentally
derived mRNA sequences (cTAGE-1, cTAGE-2, or expressed
sequence tags). Thus this gene may indeed be spliced into several
variants.
RT-PCR analysis revealed that cTAGE-1 was present in 35%
of the CTCL tumor specimens and all four CTCL cell lines, but
a second primer pair II, which should detect cTAGE-2, could not
be found in any of the tumor specimens (Table I). This indicates
the expression of a shorter splicing variant of cTAGE-2 instead of
the full-length cTAGE-2 within the normal tissues, as cTAGE-1-
speci¢c primer set I would also detect the latter. In fact, an
additional 30RACE starting within cTAGE-2 and using testis as
template led to several products, among them the already known
30 end given by cTAGE-1 (Fig 1) and another, shorter product,
which can explain the above-mentioned RT-PCR results and
was named cTAGE-2s (Fig 1). Thus, cTAGE-1 and cTAGE-2s
were never coexpressed with the exception of testis tissue.
The expression of the di¡erent splicing forms could be
deduced from the combination of three di¡erent primer sets
(cTAGE-1 mRNAwill be ampli¢ed by primer set I, cTAGE-1B
by primer sets I and II, cTAGE-1C by primer set II, cTAGE-2 by
all three primer sets, and cTAGE-2s by primer sets II and III; see
Fig 1). All cTAGE-1/2 splicing forms were isolated from testis
libraries; thus all of them are expressed in testis tissues.
Among 28 analyzed normal tissues cTAGE-1, cTAGE-1B, and
cTAGE-2 could be detected only in testis, whereas cTAGE-2s and
cTAGE-1C expression analysis gave positive results in 21% and
14% of the normal tissues, respectively (Table I). Furthermore
cTAGE-1 and probably cTAGE-1B, but not cTAGE-2, were
found in tumor-derived material (see Table I). Thus cTAGE-1
and cTAGE-1B are cancer germline genes.
Epitope mapping of anti-cTAGE-1 protein reactivity As
cTAGE-1 did not possess an obvious open reading frame, we
analyzed all possible peptides coded by the plus strand in all
three frames by epitope mapping. Two di¡erent sera from
CTCL patients, but neither of two normal sera, detected several
15mers of the longest possible open reading frame (74 amino
acids) in the second frame beginning at bp 14 as the
immunoreactive target of the patients’ antibodies. The epitope
could be deduced as being 9 amino acids in length
(FVLFLFGGN; see Fig 2). Computational analysis of cTAGE-1
protein revealed a molecular mass of 8.4 kDa and an isoelectric
point of 5.49.
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Towards de¢ning the cTAGE family As Northern blotting
using a probe derived from cTAGE-1 pointed already towards
the possibility that cTAGE-1 belongs to a larger gene family
(Eichmˇller et al, 2001), we did a Southern blot analysis using
genomic DNA from the CTCL cell lines MyLa, HH, HuT-78,
and SeAx digested by HindIII and incubated these with two
di¡erent radioactive probes (Fig 3). One probe derived from
cTAGE-1 labeled only one band at 4.3 kb, indicating that no
other cTAGE-1 homologous sequence is present within the
genome besides the predicted fragment on chromosome 18p11.2.
In contrast, a probe derived from the coding sequence of cTAGE-
2 marked at least 10 distinct bands characteristic for a multigene
family. Within the restriction fragments from chromosome
18p11.2 this probe should label only the same 4.3 kb fragment as
the cTAGE-1 probe. This con¢rms the existence of a gene family
suggested by results of the Northern blot analysis published
before (Eichmˇller et al, 2001).
In order to identify more homologous genes we performed a
cDNA library screening of 1.2105 plaques using digoxigenin-
labeled PCR products derived from cTAGE-1 and cTAGE-2 as
probes and a testis phage library (Eichmˇller et al, 2001). We
could isolate six clones: two of them were identical to cTAGE-1
and four clones represented new cDNAs named cTAGE-3,
cTAGE-4, cTAGE-5A, and cTAGE-5B (Accession numbers
AF338231-AF338234). These new mRNAs shared moderate to
high sequence homology to cTAGE-2, as well as to MEA/
MGEA-6 and MEA/MGEA-11 (Heckel et al, 1997), SEREX-
de¢ned, meningioma-associated antigens. Moreover, the already
mentioned 30 RACE starting from cTAGE-2 led to a sequence
resembling cTAGE-4 as well as MGEA-11.
The mRNA alignment of all cTAGE and MGEA/MEA
antigens showed strong homology within the coding sequence
ranging from 88% to 99% in the overlapping region. Striking
di¡erences between all sequences were found in the 50 and
especially in the 30 untranslated regions. Notably, cTAGE-1 is
located in the 30 region of cTAGE-2 and displayed no homology
to the other cTAGE members (less than 42% similarity).
The amino acid sequence homologies among the cTAGE
members were in the range from 74% to 89%, whereas the four
splicing variants of cTAGE-5 showed more than 98% homology
to each other.
cTAGE-5: Splicing variants from chromosome 14 cTAGE-
5A and cTAGE-5B could be identi¢ed as splicing variants from
chromosome 14 (Accession number AL157791, version 4), both







(various organs)b MF SS TZL CD30þ Total CTCL cell lines (n¼ 4)
cTAGE-1 1284 18p11.2 1/28 5/14 1/3 þ ^ 37% 100%f
cTAGE-1B 2296 18p11.2 1/28 0/6 0/3 ^ ^ 0% 100%f
cTAGE-1C 1347 18p11.2 4/28 0/6 0/3 ^ ^ 0% 100%f
cTAGE-2s 3607 18p11.2 6/28 0/6 0/3 ^ ^ 0% 0%
cTAGE-2 4345 18p11.2 1/28 0/6 0/3 ^ ^ 0% 0%
cTAGE-3 2277 13d 9/28 4/11 0/3 þ ^ 31% 0%
cTAGE-4 1967 7e 3/28 2/11 0/3 ^ ^ 13% 0%
cTAGE-5A 2778 14 1/28 4/11 0/3 ^ ^ 25% 100%
cTAGE-5B 4110 14 4/28 2/11 0/3 þ ^ 19% 0%
cTAGE-5C/MGEA-6 3676 14 9/28 1/6 0/3 ^ ^ 9% 25%
cTAGE-5D/MGEA-11 2814 14 4/28 0/6 0/3 ^ ^ 0% 25%
acTAGE-1/2 belong to the same gene on chromosome 18p11.2 (cf. Fig 1), whereas cTAGE-5A through cTAGE-5D belong to the same gene on chromosome 14
(cf. Fig 4). All similarities between mRNA sequences and chromosomal sequences were larger than 99.1%.
bPositive tested normal tissues: cTAGE-1, testis; cTAGE-1B, testis; cTAGE-1C, fetal brain, lung, skeletal muscle and testis; cTAGE-2s, ovary, skin, spleen, stomach, testis,
and trachea; cTAGE-2, testis only; cTAGE-3, fetal brain, fetal heart, fetal spleen, colon, mammary gland, ovary, placenta, stomach, and testis; cTAGE-4, placenta, skin, and
testis; cTAGE-5A, testis only; cTAGE-5B, placenta, small intestine, stomach, and testis; cTAGE-5C/MGEA-6, bone marrow, brain, colon, placenta, prostate, skeletal
muscle, small intestine, testis, and trachea; cTAGE-5C/MGEA-11, colon, prostate, skeletal muscle, and testis; all other normal tissues were tested negative.
cMF, mycosis fungoides; SS, SeŁ zary syndrome; TZL,T-zone lymphoma; CD30
þ, CD30-positive CTCL.
dChromosomal localization uncertain; for details see text.
eSequences from chromosome 7q33 and 6 showed a slightly lower similarity (see text).
fPrimer set I and II positive; thus uncertain expression pro¢le in this case.
Figure 2. Epitope mapping of the reactive peptide sequence from
cTAGE-1 as detected by sera from CTCL patients. All possible open
reading frames were synthesized as 15mers with a 1 amino acid shift on an
activated membrane and incubated with the patient’s serum. Speci¢c bind-
ing was detected via a human-IgG-speci¢c, horseradish-peroxidase-
coupled secondary antibody.
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showing 99.9% similarity with the genomic sequence. Recently,
MGEA-6 and MGEA-11 have been attributed to chromosome 14
as well (Comtesse et al, 2001). Unfortunately, Comtesse et al used a
chromosomal sequence that has meanwhile been withdrawn. As
we could align cTAGE-5C/MGEA-6 and cTAGE-5D/MGEA-11
to the same gene on chromosome 14, this gene gave rise to at least
four di¡erent splicing variants by variable combinations of 26
exons (Fig 4): cTAGE-5A skipped exon 2, cTAGE-5B exons 1
and 25, cTAGE-5C/MGEA-6 exons 1 and 26, and cTAGE-5D/
MGEA-11 exons 1, 20, and 26.
Interestingly, the mRNA expression as analyzed by RT-PCR
revealed a di¡erential or tumor-speci¢c appearance depending
on the splicing variant (see Table I). cTAGE-5A was expressed
only in CTCL tumor specimens (25%) and CTCL cell lines
(four of four), but not in normal tissues besides testis. In contrast,
cTAGE-5B, cTAGE-5C/MGEA-6, and cTAGE-5D/MGEA-11
were detected also in normal tissues (14%, 32%, and 14%,
respectively), as well as in CTCL tumor tissues except cTAGE-
5D/MGEA11 (19%, 9%, and 0%, respectively; see Table I). As
the coding sequence of all four splicing variants is mainly
located within the highly homologous central region, the
similarity of the deduced proteins is at least 98%. Thus, cTAGE-
5 expression was analyzed in more detail by quantifying mRNA
(Northern blot) and protein (Western blot) and by studying the
presence of speci¢c mRNA in a number of di¡erent tumors by
RT-PCR (see below).
Di¡erentially expressed genes: cTAGE-3 and cTAGE-4 The
mRNA sequence of cTAGE-3 shared 91.8% homology in
nucleotides and 82.3% in amino acid sequence with cTAGE-2.
RT-PCR using cTAGE-3-speci¢c primers identi¢ed 32%
positive normal tissues including colon, mammary gland, ovary,
placenta, stomach, and testis, as well as several fetal tissues (see
Table I).
Using RT-PCR we found cTAGE-4 within the
immunoprivileged tissues testis and placenta, as well as skin
(Table I). Moreover, 13% of the CTCL tissues, but none of the
CTCL cell lines, were positive in RT-PCR. By using a more
sensitive technique (hybridization of RT-PCR products, see
Materials and Methods) the number of positive CTCL tumor
tissues was higher (31%), whereas the number of positive
normal tissues increased only from three to ¢ve of 28
(additionally positive: mammary gland and stomach).
Northern and Western blot analysis Northern blot analysis
was performed to quantify the mRNA expression level of the
cTAGE family members (see Fig 5). A radioactive-labeled DNA
probe derived from a PCR using primer set II and cTAGE-2
plasmid was used, which may also hybridize with the other
cTAGE members. The expression of the cTAGE members was
usually stronger in tumor-derived tissues than in normal tissues.
Strong signals were detected in normal testis, HH (CTCL cell
line), Colo320, HT 29 (colon carcinoma cell lines), and UKRV-
Mel27 (a melanoma cell line), whereas only weak signals were
Figure 3. Southern blot with either a cTAGE-1 probe (A) or a cTAGE-2
probe (B). HindIII digested genomic DNA from four di¡erent CTCL cell
lines was used. The latter most probably hybridized with all cTAGE mem-
bers and depict several chromosomal sequences typical for a multigene fa-
mily. Hybridization with a control probe resulted in no staining (not
shown). (C) Restriction of chromosome 18p11.2 and localization of
cTAGE-1, cTAGE-2, and the related probes. Both should label a 4.4 kb
fragment.
Figure 4. Graphical alignment of the cTAGE-5 splicing variants and chromosome 14.
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seen in some of the normal tissues (Fig 5). At least two di¡erent
transcripts could be observed, representing di¡erent cTAGE
members. Whereas the cTAGE-5B and cTAGE-2 mRNAs were
predicted as 4.1 and 4.3 kb and thus corresponded to the large
band in the Northern blots, the small band ¢tted to the sizes of
cTAGE-1B, cTAGE-3, and/or cTAGE-4 (1.9^2.3 kb).
The presumption of the Northern blot analysis that the cTAGE
transcripts may be overexpressed in tumor tissues was supported
byWestern blot analysis.We generated a rabbit antibody against a
15 amino acid peptide derived from cTAGE-5A, which is also
present in cTAGE-5C/MGEA-6 and cTAGE-5D/MGEA-11. The
peptide-puri¢ed antibody K64 did not label any speci¢c band in
any of the RT-PCR-positive normal tissues, but did so in a
number of cell lines of di¡erent types of tumors (one
representative example is given in Fig 6): the CTCL cell lines
HH, HuT78, MyLa, SeAx, the colon carcinoma cell lines HT29
and Colo320, and the melanoma cell lines Ma-Mel-33 and
UKRV-Mel-11. Interestingly, two di¡erent bands (88 kDa and
35 kDa) could be observed in the tumor protein samples, which
may re£ect a degradation phenomenon.
Genomic analysis In contrast to cTAGE-5, all other cDNAs
were found as singular exons localized on di¡erent
chromosomes, which might be interpreted as processed
pseudogenes or intronless genes. cTAGE-1C was the only
exception as it possessed a small intron. Our experimental data
(RT-PCR, Northern blot, antibody reactivity) strongly suggest
that these sequences are intronless genes. We additionally
performed extensive in silico analyses including alignment of the
cDNAs to the chromosomal sequences, prediction of promoter
and possible exons, as well as analysis of putative SINE and
LINE sequences, all supporting the conclusion that the
identi¢ed cTAGE sequences are transcribed genes.
All chromosomal sequences displayed considerable numbers of
ALU sequences (ranging from 5% to 16.7%), but not in close
proximity to the corresponding cTAGE genes. The only
exception was cTAGE-2, where ALU sequences were localized
1607 bp upstream and 2615 bp downstream of cTAGE-2 on
chromosome 18p11.2. Interestingly, the predicted promoter was
found 2797 bp upstream of cTAGE-2; thus the 50 ALU sequence
was found between promoter and transcript.
cTAGE-3 ¢tted to a sequence from chromosome 13 (Accession
number AL138821; 98.8% similarity, promoter 10 kb upstream).
cTAGE-4 could be aligned to three di¡erent chromosomal
sequences: (i) chromosome 7 (Accession number AC074386,
99.7% similarity); the predicted gene consisted of a promoter
Figure 5. cTAGE Northern blot analysis. Two di¡erent transcripts (approximately 4.3 and 1.8 kb) were detected by Northern blot analyses using a
cTAGE-2-speci¢c probe, which may also hybridize to other cTAGE family members. Ten micrograms total RNAwas used from 14 normal tissues (North-
ern blot A, 1, bone marrow; 2, brain; 3, colon; 4, kidney; 5, liver; 6, breast; 7, placenta; 8, prostate; 9, skeletal muscle; 10, skin; 11, small intestine; 12, thymus; 13,
trachea; 14, testis; Northern blot B, 9, 10, testis) and from 22 tumor-derived cell lines (A, 15, HH; 16, Colo320; 17, HT29; 18, Ma-Mel-33; 19, UKRV-Mel-11a;
20, HH; 21, HuT-78; 22, MyLa; 23, SeAx; B, 1, Ma-Mel-21; 2, Ma-Mel-22; 3, UKRV-Mel-14a; 4, UKRV-Mel-06a; 5, UKRV-Mel-37; 6, SK-Mel-29; 7,
WM98-1; 8, Ma-Mel-18a; 11, UKRV-MEL-17; 12, UKRV-MEL-27; 13, UKRV-MEL-20c; 14, UKRV-Mel-38c; 15, UKRV-Mel-21a; 16, Ma-Mel-11). In sev-
eral RNA samples only a faint labeling could be detected (small arrows), mainly demarcating the large transcript. In addition, a strong signal (large arrows) was
seen for the larger band in testis and four cell lines (HH, Colo329, HT29, and UKRV-Mel-27) and the small band in the cell line HT29.
Figure 6. Western blot analysis of tumor cell lines and normal tis-
sues using an anti-cTAGE-5A peptide-speci¢c antibody. The cell
lines were derived from CTCL (MyLa), colon carcinoma (Colo320,
HT29), and melanoma (Ma-Mel-33, UKRV-Mel-11). cTAGE-5A-positive
cell lines showed two di¡erent bands. Although the depicted 88 kDa band
corresponded to the predicted size, a smaller degradation product of ap-
proximately 35 kDa appeared as a second, strong signal. Except testis, all
normal protein lysates were tested negative.
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and 15 exons, of which the terminal exon is the largest and
highly similar to cTAGE-4; (ii) chromosome 7q33^35 (Acces-
sion number AC005587, 99.2% similarity, promoter 3894 bp
upstream); and (iii) chromosome 6 (Accession number
AL135904, 99.3% similarity, no promoter).
Serologic reactivity to all cTAGE proteins The presence of
antibodies in the serum of patients and healthy donors was
tested with all newly identi¢ed genes except cTAGE-1B,
cTAGE-1C, and cTAGE-2. cTAGE-3, cTAGE-4, cTAGE-5A, and
cTAGE-5B were isolated as l-phage clones and could therefore
be used for re-screening by SEREX with di¡erent sera from
patients su¡ering from CTCL or melanoma, as well as healthy
controls (seeTable II).
We found only one normal serum reacting with cTAGE-3,
whereas all other normal sera (n¼14) were negative for all
cTAGE clones. In contrast, sera from CTCL patients reacted
with cTAGE-1, cTAGE-3, cTAGE-4, and cTAGE-5A, whereas
sera from melanoma patients recognized cTAGE-1 and cTAGE-
5B (Table II).
Expression analysis of cTAGE-1, cTAGE-4, cTAGE-5A, and
cTAGE-5B in various malignancies We have performed
additional RT-PCR expression analysis of those cTAGE
members whose expression was tumor speci¢c (cTAGE-1 and
cTAGE-5A) or that were recognized by patients’ sera only
(cTAGE-1, cTAGE-4, cTAGE-5A, and cTAGE-5B) within tumor
specimens of various origins. As previously described, cTAGE-1
was detectable in 46% of CTCL tissues (including cell lines),
but not in melanoma and leukemia cell lines (Eichmˇller et al,
2001). In addition, we could ¢nd cTAGE-1 in carcinomas of
colorectal (15% of the tested specimens) and mammary gland
(43%) origin, as well as in head and neck squamous cell
carcinomas (26%; see Table III). cTAGE-4, cTAGE-5A, and
cTAGE-5B could be detected in 0^60% of the investigated
specimens of all tumor entities mentioned above (Table III).
With a higher sensitivity by hybridizing the blotted PCR
products the percentage of positive tumor samples and cell lines
increased (cTAGE-4, CTCL 25% and melanoma 50%; cTAGE-
5A, CTCL 48%, colorectal cancer 50%, head and neck
squamous cell carcinoma 20%, and melanoma 52%; cTAGE-5B,
CTCL 47% and melanoma 65%). In contrast, the number of
normal tissues was unchanged using this sensitive method in the
cases of cTAGE-1 and cTAGE-5A, and was slightly increased in
the cases of cTAGE-4 (¢ve of 28 instead of three of 28) and
cTAGE-5B (eight of 28 instead of four of 28).
DISCUSSION
Knowledge of tumor-specifc antigens is the prerequisite for suc-
cessful immunotherapies. For CTCL, which is a malignancy of
mainly the CD4 T lymphocytes, only very few speci¢c antigens
have been identi¢ed to date: a tumor-associated receptor mole-
cule, SC5, with an increased expression on tumor cells has re-
cently been described (Nikolova et al, 2001); the TCR itself has
been proposed as target (Berger et al, 1998); but no publications
are at present available proving the feasibility of using TCR-re-
lated epitopes as speci¢c targets. The frequent detection of circu-
lating tumor cells (Dummer et al, 1996; Muche et al, 1997) and the
correlation of a systemic immune response with a good prognosis
(Asadullah et al, 1997) suggest that CTCL is susceptible to immu-
notherapeutic approaches ^ possibly even without measurable lo-
cal antitumor response.
We have recently identi¢ed cTAGE-1 as the ¢rst tumor-speci¢c
antigen (Eichmˇller et al, 2001). Sequence analysis and Northern
blotting suggested that cTAGE-1 is a splicing product of a larger
gene.
In fact, a 50 RACE elongation using cDNA derived from
healthy testicular tissue led to a full-length gene (cTAGE-2),
which could be con¢rmed by alignment with the appropriate
genomic sequence of chromosome 18p11.2. Together with two
mRNAs published as expressed sequence tags and subsequently
sequenced by us (cTAGE-1B and cTAGE-1C), and another shor-
tened version of cTAGE-2, named cTAGE-2s, we conclude that
this gene located on 18p11.2 is di¡erentially spliced into at least
¢ve di¡erent mRNAs. Interestingly, these splicing forms showed
a very speci¢c expression pattern (Fig 1,Table I) with cTAGE-1
and cTAGE-1B expressed only in testis and tumors and cTAGE-2
only in testis.
cTAGE-2 was identi¢ed as being part of a larger gene family
by Southern analysis. Subsequently, screening for other members
of the cTAGE family unraveled another four cDNA sequences
with putative genomic localizations on chromosomes 6/7, 13,
and 14.
Two of the sequences (cTAGE-5A and cTAGE-5B) are splicing
variants of the same gene localized on chromosome 14 and
cTAGE-5A turned out to be a second cancer germline gene ex-
pressed in CTCL. Moreover, another two published sequences,
MGEA/MEA-6 and MGEA/MEA-11 (Heckel et al, 1997), are
further splicing variants of the cTAGE-5 gene. Interestingly,
whereas cTAGE-5 is composed of at least 26 exons di¡erentially
spliced (cf. Fig 4), all other cTAGE members are found as intron-
less genes. By computational analyses Comtesse et al (2001) iden-
ti¢ed several MGEA homologs on various chromosomes, which
they have attributed as processed pseudogenes due to their un-
spliced appearance.
At least for the cTAGE members described in this paper we can
exclude that these genes are pseudogenes for several reasons: (i)
we have identi¢ed all cTAGE sequences from a cDNA library
made from DNAse-treated testis mRNA; (ii) their expression
was con¢rmed by RT-PCRusing cDNAs independently derived
from various specimens and by Northern blot; (iii) expressed
sequence tags have been described for cTAGE-1 derived from
Table II. Serologic recognition of recombinantly expressed
cTAGE proteinsa
CTCL sera Melanoma sera Sera from healthy donors
cTAGE-1b 33% (30) 7% (15) 0% (17)
cTAGE-3 10% (21) 0% (15) 7% (14)
cTAGE-4 5% (21) 0% (15) 0% (14)
cTAGE-5A 15% (20) 0% (15) 0% (14)
cTAGE-5B 0% (22) 13% (15) 0% (14)
aAs analyzed by SEREX with various sera from patients and control donors
against the detected phage clones. No phage clones were available from cTAGE-
1B, cTAGE^1C, and cTAGE-2.
bAs described in Eichmuº ller et al, 2001with additional sera tested.
Table III. Frequency of cTAGE-1, cTAGE-4, cTAGE-5A, and
cTAGE-5B expression in various tumor entities as detected by
RT-PCR
cTAGE-1 cTAGE-4 cTAGE-5A cTAGE-5B
Cell type Positive (n) Positive (n) Positive (n) Positive (n)
CTCLa,b 46% (24)c 10% (20) 44% (18) 16% (19)
Colorectal
carcinomasa
15% (39) 20% (10) 33% (39) 60% (10)
Breast
carcinomas
43% (23) 60% (10) 20% (10) 20% (10)
HNSCCa,b 26% (34) 30% (10) 0% (10) 50% (10)
Melanomaa 0% (29)c 23% (22) 25% (20) 19% (16)
aAlso cell lines included.
bSeparate results on tissues and cell lines seeTable I.
cSome of these data as published in Eichmuº ller et al, 2001.
dHNSCC, head and neck squamous cell carcinoma.
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independent libraries; and (iv) we can show reactive antibodies
against all tested members in sera of CTCL and/or melanoma pa-
tients. Genomic contamination can be excluded due to consistent
negativity in control PCR using the same RNA samples from
which cDNA was made. Moreover, genomic contamination
should have been visible as a 2.8 kb band when cTAGE-5A is am-
pli¢ed by RT-PCR, which was never the case, even when the
very sensitive DNA hybridization of the PCR products was per-
formed.
It is very likely that cTAGE-2, cTAGE-3, and cTAGE-4 have
developed through retroposition. By analyzing the exons within
the cTAGE-5 gene we found that the other cTAGE members are
most probably derived from a splicing variant composed of exons
2^26. Whereas the cTAGE-4 variant found on chromosome 6
might re£ect a processed pseudogene not being transcribed
(Maestre et al, 1995; Mighell et al, 2000), the other cTAGE se-
quences can be assigned as either intronless genes with a demon-
strable promoter (cTAGE-1, cTAGE-2, cTAGE-3, and two
chromosomal homologs of cTAGE-4) or as normal genes con-
taining a considerable number of introns (cTAGE-1C, cTAGE-5,
and the gene on chromosome 7 containing a cTAGE-4 homolo-
gous sequence).
In spite of missing introns within cTAGE-1 to cTAGE-4, spli-
cing seems to have an important impact on the expression of at
least two genes of the cTAGE family: cTAGE-1 and cTAGE-1B
are tumor-speci¢c splicing variants of cTAGE-2. Another spli-
cing variant, named cTAGE-2s, has been deduced indirectly from
expression analysis and RACE elongation results. cTAGE-1 and
cTAGE-2s are never coexpressed with the exception of testis tis-
sue: testis is positive for all three primer sets and all genes were
isolated from testis.
Tissue-speci¢c splicing is a well-known phenomenon and in-
cludes some examples concerning tumor dependency, e.g., CD44
splicing products are used as a possible factor for prognostic issues
and metastatic state (Ponta et al, 1994; Seiter et al, 1996; Goodison
et al, 1999), and tumor suppressor genes like p53 (Wu et al, 1994) or
WT-1 (Larsson et al, 1995) show a tumor-speci¢c splicing. Most
recently, di¡erential splicing was demonstrated for CD95 (Apo-
1/fas) in CTCL tumor cells: the retention of intron number 5 re-
sulted in a truncated protein without the death domain (van
Doorn et al, 2002).
A large multiexon gene on chromosome 14 is spliced into
cTAGE-5A, cTAGE-5B (this work), cTAGE-5C/MGEA-6, and
cTAGE-5D/MGEA-11 (Comtesse et al, 2001), but only cTAGE-
5A is a true cancer germline gene, being expressed only within
testis and tumor tissues  on the basis of RT-PCR results. Based
on our Western blot experiments, the protein expression of
cTAGE-5A, cTAGE-5C, and cTAGE-5D is tumor speci¢c as in-
vestigated by a peptide-speci¢c, peptide-puri¢ed rabbit antibody.
This is in agreement with a protein expression analysis published
very recently by Comtesse et al (2002), who used a polyclonal rab-
bit antibody speci¢c for MGEA-6 and MGEA-11, which will
most probably also detect cTAGE-5A and cTAGE-5B.
The remaining cTAGE family members (cTAGE-3 and
cTAGE-4) were di¡erentially expressed in normal tissues when
analyzed by RT-PCR.We are trying to obtain speci¢c antibodies
to investigate the protein expression of the di¡erent cTAGE
members. Expression levels of corresponding proteins are critical
for the value of the various cTAGE members as tumor targets.
For example it is known that NY-ESO-1 is highly tumor speci¢c
when analyzed by Northern blotting or serologic reactivity
(Stockert et al, 1998), but mRNA can be detected in normal tis-
sues by RT-PCR (Chen et al, 1997). Further, a variety of tumor
antigens are characterized by overexpression within tumor tissues
compared to normal counterparts, e.g., Her2/neu (Green et al,
2000;White et al, 2001).
Additional RT-PCR expression analysis using tumor tissues of
various origins and speci¢c primer sets for cTAGE-1, cTAGE-4,
cTAGE-5A, and cTAGE-5B revealed highly variable frequencies
of expression depending on tumor type and antigen. Notably, for
each type of tumor at least one cTAGE member was detected at a
high rate (Table III): CTCL, cTAGE-1 (46%); colorectal carcino-
ma, cTAGE-5B (60%); breast carcinoma, cTAGE-4 (60%); head
and neck squamous cell carcinoma, cTAGE-5B (50%); and mela-
noma, cTAGE-5A (25%).
A great advantage of the strategy used for identi¢cation of tu-
mor antigens is the availability of phage clones, which directly
allows the analysis of serum reactivity against recombinant pro-
tein. cTAGE-1, cTAGE-4, cTAGE-5A, and cTAGE-5B were de-
tected by cancer-related sera only (seeTable II), whereas cTAGE-
3 was also recognized by one normal serum (n¼14). Highest ser-
um reactivity within CTCL patients was found against cTAGE-1
(33%; n¼ 30), whereas only three of 20 sera detected cTAGE-5A.
Interestingly, meningioma patients have also been found to react
against MGEA-6/11 (Comtesse et al, 2002).
In addition, we have identi¢ed the immunogenic epitope of
cTAGE-1 as a 9 amino acid sequence. This proves the translation
of the longest possible open reading frame within cTAGE-1,
which is only 74 amino acids in size, and opens the possibility
of generating an epitope-speci¢c antibody for further studies.
Avariety of cancers have meanwhile been intensively tested for
tumor targets (Rosenberg, 2001), but CTCL is at present not one
of the main targets of immunotherapeutic strategies (Eichmˇller,
2002). This might be due to the low frequency of expression of
known cancer germline genes, although we recently detected
LAGE-1, MAGE-A9, and GAGE-3GAGE-7 in CTCL speci-
mens (Eichmˇller et al, 2003).
On the basis of the expression analysis presented here we can
conclude that cTAGE-1 and cTAGE-5 belong to the so-called
cancer-testis antigens, as their expression is limited to testis and
cancer tissues (Old, 2001). Human-leukocyte-antigen-dependent
epitopes for speci¢c recognition by cytotoxicTcells are at present
being investigated. In summary, cTAGE-1 and cTAGE-5 are pro-
mising target proteins for CTCL and are candidate targets for
other types of tumors.
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